More recently, studies with human prostate cancer cell lines and tissues have identified the presence of AR splice variants (AR-Vs) which can be up-regulated in response to castration and promote resistance to androgen receptor targeted therapy [7–9] [10] [11]. This evidence concerns the gene AR and prostate carcinoma.